Is Long-acting Cabotegravir a Pre-exposure Prophylaxis Option for Women of Childbearing Potential?

Open Forum Infect Dis. 2022 May 11;9(7):ofac230. doi: 10.1093/ofid/ofac230. eCollection 2022 Jul.

Abstract

Long-acting cabotegravir (CAB-LA) provides an exciting new option for pre-exposure prophylaxis (PrEP) in multiple populations. In this Perspective, we consider the unique pharmacokinetics of CAB-LA and the potential impact on the prescribing of CAB-LA, specifically in cis-women of reproductive potential.

Keywords: HIV; cabotegravir; pre-exposure prophylaxis; women.